<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624010</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-LVO-05</org_study_id>
    <nct_id>NCT03624010</nct_id>
  </id_info>
  <brief_title>Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients</brief_title>
  <official_title>Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tenax Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tenax Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PH-HFpEF patients will receive weekly open-label doses of levosimendan and be periodically&#xD;
      evaluated for safety and effectiveness in extended use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll PH-HFpEF patients that have completed a controlled levosimendan study.&#xD;
      These patients will receive weekly open-label doses of levosimendan and be periodically&#xD;
      evaluated for safety and effectiveness in extended use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Safety measured by number of adverse events (AEs )</measure>
    <time_frame>2 years</time_frame>
    <description>Long-term safety profile of levosimendan measured by number of adverse events (AEs )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test (6MWT)</measure>
    <time_frame>2 years</time_frame>
    <description>Exercise capacity, measured as a distance traveled in 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>2 years</time_frame>
    <description>Patient's assessment of well-being, based on a six-point Likert scale (1 =worst, 5= best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Assessment of Functional Class</measure>
    <time_frame>2 years</time_frame>
    <description>Physician's Assessment of New York Heart Association (NYHA) Classification (one of four categories based on how much the patient is limited during physical activity. (Class I, no limitation of physical activity to Class IV, marked limitation of physical activity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Events: Death and hospitalizations</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of death or hospitalization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hypertension Pulmonary Secondary Heart Failure</condition>
  <condition>Right Sided Heart Failure With Normal Ejection Fraction</condition>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan 2.5 mg/ml Injectable Solution</intervention_name>
    <description>A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide a personally signed and dated informed consent document prior to initiation of&#xD;
             any study-related procedures that are not considered standard of care.&#xD;
&#xD;
          2. Completed double-blind therapy in a PH-HFpEF clinical study sponsored by Tenax&#xD;
             Therapeutics, Inc.&#xD;
&#xD;
          3. May, in the opinion of the Investigator, benefit from continued levosimendan&#xD;
             treatment.&#xD;
&#xD;
          4. Female patients of childbearing potential must agree to use a highly effective method&#xD;
             of contraception.&#xD;
&#xD;
          5. Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Discontinued treatment in the parent study for any reason other than study completion&#xD;
             or Sponsor termination of the study.&#xD;
&#xD;
          2. Pregnant or breastfeeding women.&#xD;
&#xD;
          3. Local access to commercially available levosimendan&#xD;
&#xD;
          4. Inability to comply with planned study procedures&#xD;
&#xD;
          5. Patients with scheduled lung or heart transplant or cardiac surgery&#xD;
&#xD;
          6. Dialysis developed since enrollment in parent study (either hemodialysis, peritoneal&#xD;
             dialysis, continuous venovenous hemofiltration, or ultrafiltration)&#xD;
&#xD;
          7. Estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73m2&#xD;
&#xD;
          8. Liver dysfunction with Child Pugh Class B or C (see Attachment 2)&#xD;
&#xD;
          9. Evidence of systemic bacterial, systemic fungal, or viral infection refractory to&#xD;
             treatment&#xD;
&#xD;
         10. Weight &gt;150kg&#xD;
&#xD;
         11. Systolic blood pressure (SBP) cannot be managed to ensure SBP &gt;100 mmHg at initiation&#xD;
             of study drug&#xD;
&#xD;
         12. Heart rate &gt;100 bpm with study drug, persistent for at least 10 minutes at screening.&#xD;
&#xD;
         13. Hemoglobin &lt; 80 g/L&#xD;
&#xD;
         14. Serum potassium &lt; 3.0 mmol/L or &gt; 5.5 mmol/L at baseline that is unresponsive to&#xD;
             management&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Rich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tenax Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Healthcare</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Health University Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Dextrocardia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

